LMR Partners’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

LMR Partners’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-71,918	Closed	-$336K	–	1585
2022 Q1	$336K	Buy	+71,918	New	+$214K	﹤0.01%	1055
2021 Q2	–	Sell	-37,769	Closed	-$110K	–	1593
2021 Q1	$110K	Buy	+37,769	New	+$123K	﹤0.01%	852
2019 Q4	–	Sell	-54,931	Closed	-$46K	–	640
2019 Q3	$46K	Hold	54,931	–	–	﹤0.01%	379
2019 Q2	$47K	Buy	+54,931	New	+$50.7K	﹤0.01%	380
2016 Q3	–	Sell	-23,505	Closed	-$80K	–	595
2016 Q2	$80K	Buy	+23,505	New	+$108K	0.01%	413
2014 Q2	–	Sell	-10,364	Closed	-$352K	–	655
2014 Q1	$352K	Buy	+10,364	New	+$354K	0.05%	169

Other funds holding CTIC

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

LMR Partners's CTIC Position: Q2 2022 in Review

LMR Partners sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2022, closing a stake of 71,918 shares — an estimated $336K sold.

LMR Partners first reported a position in CTIC in Q1 2014 and held it in 6 quarters. The position peaked at $352K in Q1 2014. 119 funds tracked by Wall St. Rank hold CTIC as of Q2 2022.

LMR Partners reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2022 after selling out during the quarter.
LMR Partners sold 71,918 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2022, an estimated $336K.
LMR Partners first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2014 and held it in 6 quarters.
LMR Partners's CTI BioPharma Corp. (DE) Common Stock position peaked at $352K in Q1 2014.
119 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2022.

Based on LMR Partners's 13F filing for Q2 2022, filed 15 Aug 2022.